![](https://endpts.com/wp-content/uploads/2021/06/Bing-Yao-ArriVent-tile-scaled.jpg)
Bing Yao, ArriVent Biopharma CEO
ArriVent prices $175M IPO in back-to-back oncology biotech listings
ArriVent Biopharma will join the Nasdaq on Friday morning in a strong start to biotech’s first batch of initial public offerings this year.
The Pennsylvania …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.